Intolerable side effects during propranolol therapy for infantile hemangioma: frequency, risk factors and management

Currently, propranolol is the most preferred systemic therapy for problematic infantile hemangiomas (IHs). However, the side effects such as bronchial hyperreactivity may be intolerable. The aim of this study was to evaluate the frequency, risk factors and management of intolerable side effects (ISE...

Descripción completa

Detalles Bibliográficos
Autores principales: Ji, Yi, Chen, Siyuan, Wang, Qi, Xiang, Bo, Xu, Zhicheng, Zhong, Lin, Yang, Kaiying, Lu, Guoyan, Qiu, Liqin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844887/
https://www.ncbi.nlm.nih.gov/pubmed/29523832
http://dx.doi.org/10.1038/s41598-018-22787-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844887/
https://www.ncbi.nlm.nih.gov/pubmed/29523832
http://dx.doi.org/10.1038/s41598-018-22787-8

Ejemplares similares